Myeloid cell-specific serine palmitoyltransferase subunit 2 haploinsufficiency reduces murine atherosclerosis

Journal of Clinical Investigation

Volumn 123, Issue 4, 2013, Pages 1784-1797

  Chakraborty, Mahua ^a   Lou, Caixia ^a,b   Huan, Chongmin ^a   Kuo, Ming Shang ^c   Park, Tae Sik ^d   Cao, Guoqing ^c,e   Jiang, Xian Cheng ^a,f  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b MINZU UNIVERSITY OF CHINA   (China)

^c ELI LILLY AND COMPANY   (United States)

^d Gachon University   (South Korea)

^e Jiangsu Hengrui Medicine   (China)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SERINE PALMITOYLTRANSFERASE; SERINE PALMITOYLTRANSFERASE SUBUNIT 2; SPHINGOMYELIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BONE MARROW CELL; CELL MEMBRANE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FEMALE; HAPLOINSUFFICIENCY; INFLAMMATION; LIPID RAFT; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CELL MOVEMENT; CHEMOKINE CCL2; CHOLESTEROL; ENZYME ACTIVATION; FEMALE; GLUCOSYLCERAMIDES; HAPLOINSUFFICIENCY; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACROPHAGES; MEMBRANE MICRODOMAINS; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROTEIN SUBUNITS; RECEPTORS, LYSOSPHINGOLIPID; SERINE C-PALMITOYLTRANSFERASE; SPHINGOMYELINS; TOLL-LIKE RECEPTOR 4;

EID: 84875843904     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60415     Document Type: Article

References (66)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874.
2. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: Control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000;1470(2):M55-M62.
3. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3(3):221-227.
4. Grilli M, Chiu JJ, Lenardo MJ. NF-kappa B and Rel: Participants in a multiform transcriptional regulatory system. Int Rev Cytol. 1993;143:1-62.
5. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation. Genes Dev. 1995;9(22):2723-2735.
6. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 1993; 362(6423):801-809.
7. Freeman M, et al. An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors. Proc Natl Acad Sci U S A. 1990;87(22):8810-8814.
8. Cavelier C, Lorenzi I, Rohrer L, von Eckardstein A. Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim Biophys Acta. 2006;1761(7):655-666.
9. Jessup W, Gelissen IC, Gaus K, Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol. 2006;17(3):247-257.
10. Yvan-Charvet L, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 2007;117(12):3900-3908.
11. Out R, et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol. 2008;28(2):258-264.
12. Zhu X, et al. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res. 2010;51(11):3196-3206.
13. Yvan-Charvet L, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: Free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 2008;118(18):1837-1847.
14. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387(6633):569-572.
15. Li Z, et al. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization. Biochim Biophys Acta. 2007;1771(9):1186-1194.
16. Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol. 1998;275(5 pt 1):L843-851.
17. Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep. 2004;5(8):777-782.
18. Holthuis JC, van Meer G, Huitema K. Lipid microdomains, lipid translocation and the organization of intracellular membrane transport (Review). Mol Membr Biol. 2003;20(3):231-241.
19. Kim S, Watarai M, Suzuki H, Makino S, Kodama T, Shirahata T. Lipid raft microdomains mediate class A scavenger receptor-dependent infection of Brucella abortus. Microb Pathog. 2004;37(1):11-19.
20. Graf GA, Connell PM, van der Westhuyzen DR, Smart EJ. The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae. J Biol Chem. 1999;274(17):12043-12048.
21. Rhainds D, Bourgeois P, Bourret G, Huard K, Falstrault L, Brissette L. Localization and regulation of SR-BI in membrane rafts of HepG2 cells. J Cell Sci. 2004;117(pt 15):3095-3105.
22. von Arnim CA, et al. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem. 2005;280(18):17777-17785.
23. Zeng Y, Tao N, Chung KN, Heuser JE, Lublin DM. Endocytosis of oxidized low density lipoprotein through scavenger receptor CD36 utilizes a lipid raft pathway that does not require caveolin-1. J Biol Chem. 2003;278(46):45931-45936.
24. Lee HK, Dunzendorfer S, Soldau K, Tobias PS. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity. 2006;24(2):153-163.
25. Wang R, Town T, Gokarn V, Flavell RA, Chandawarkar RY. HSP70 enhances macrophage phagocytosis by interaction with lipid raft-associated TLR-7 and upregulating p38 MAPK and PI3K pathways. J Surg Res. 2006;136(1):58-69.
26. Nakahira K, et al. Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J Exp Med. 2006;203(10):2377-2389.
27. Szabo G, Dolganiuc A, Dai Q, Pruett SB. TLR4, ethanol, and lipid rafts: A new mechanism of ethanol action with implications for other receptor-mediated effects. J Immunol. 2007;178(3):1243-1249.
28. Merrill AH. Characterization of serine palmitoyltransferase activity in Chinese hamster overy cells. Biochim Biophys Acta. 1983;754(3):284-291.
29. Weiss B, Stoffel W. Human and murine serine-palmitoyl-CoA transferase-cloning, expression and characterization of the key enzyme in sphingolipid synthesis. Eur J Biochem. 1997;249(1):239-247.
30. Hanada K, Hara T, Nishijima M. Purification of the serine palmitoyltransferase complex responsible for sphingoid base synthesis by using affinity peptide chromatography techniques. J Biol Chem. 2000;275(12):8409-8415.
31. Hornemann T, Richard S, Rutti MF, Wei Y, von Eckardstein A. Cloning and initial characterization of a new subunit for mammalian serine- palmitoyltransferase. J Biol Chem. 2006;281(49):37275-37281.
32. Hornemann T, Wei Y, von Eckardstein A. Is the mammalian serine palmitoyltransferase a high-molecular-mass complex? Biochem J. 2007;405(1):157-164.
33. Han G, et al. Identification of small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA substrate specificities. Proc Natl Acad Sci U S A. 2009;106(20):8186-8191.
34. Park TS, et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2004;110(22):3465-3471.
35. Hojjati MR, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem. 2005;280(11):10284- 10289.
36. Glaros EN, et al. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem Pharmacol. 2007;73(9):1340-1346.
37. Hojjati MR, Li Z, Jiang XC. Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice. Biochim Biophys Acta. 2005;1737(1):44-51.
38. Rao KM. MAP kinase activation in macrophages. J Leukoc Biol. 2001;69(1):3-10.
39. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108(6):661-663.
40. Wang F, et al. Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoEdeficient mice. J Clin Invest. 2010;120(11):3979-3995.
41. Li Z, et al. Liver-specific deficiency of serine palmitoyltransferase subunit 2 decreases plasma sphingomyelin and increases apolipoprotein E levels. J Biol Chem. 2009;284(39):27010-27019.
42. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8(4):265-277.
43. Mitsutake S, et al. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes. J Biol Chem. 2011;286(32):28544-28555.
44. Li Z, et al. Reducing plasma membrane sphingomyelin increases insulin sensitivity. Mol Cell Biol. 2011;31(20):4205-4218.
45. Miyaji M, et al. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med. 2005;202(2):249-259.
46. Huang ZH, Gu D, Lange Y, Mazzone T. Expression of scavenger receptor BI facilitates sterol movement between the plasma membrane and the endoplasmic reticulum in macrophages. Biochemistry. 2003;42(13):3949-3955.
47. Nagao K, Takahashi K, Hanada K, Kioka N, Matsuo M, Ueda K. Enhanced apoA-I-dependent cholesterol efflux by ABCA1 from sphingomyelindeficient Chinese hamster ovary cells. J Biol Chem. 2007;282(20):14868-14874.
48. Fessler MB, Parks JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol. 2011;187(4):1529-1535.
49. Landry YD, Denis M, Nandi S, Bell S, Vaughan AM, Zha X. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem. 2006;281(47):36091-36101.
50. Peshavariya H, Dusting GJ, Di Bartolo B, Rye KA, Barter PJ, Jiang F. Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radic Res. 2009;43(8):772-782.
51. Fielding PE, Russel JS, Spencer TA, Hakamata H, Nagao K, Fielding CJ. Sterol efflux to apolipoprotein A-I originates from caveolinrich microdomains and potentiates PDGFdependent protein kinase activity. Biochemistry. 2002;41(15):4929-4937.
52. Leventhal AR, Chen W, Tall AR, Tabas I. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem. 2001;276(48):44976-44983.
53. Slotte JP. Sphingomyelin-cholesterol interactions in biological and model membranes. Chem Phys Lipids. 1999;102(1-2):13-27.
54. Bodary PF, et al. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation. 2005;111(5):629-632.
55. Glaros EN, Kim WS, Rye KA, Shayman JA, Garner B. Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. J Lipid Res. 2008;49(8):1677-1681.
56. Hailemariam TK, et al. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol. 2008;28(8):1519-1526.
57. Liu JY, Lo PC, Jiang XJ, Fong WP, Ng DK. Synthesis and in vitro photodynamic activities of di-alphasubstituted zinc(ii) phthalocyanine derivatives. Dalton Trans. 2009;(21):4129-4135.
58. Brinkmann V, Cyster JG, Hla T. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004;4(7):1019-1025.
59. Kluk MJ, Hla T. Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res. 2001;89(6):496-502.
60. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem. 2004;92(5):913-922.
61. Spiegel S, Milstien S. Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4(5):397-407.
62. Hughes JE, Srinivasan S, Lynch KR, Proia RL, Ferdek P, Hedrick CC. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res. 2008;102(8):950-958.
63. Nofer JR, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptordeficient mice. Circulation. 2007;115(4):501-508.
64. Keul P, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27(3):607-613.
65. Keul P, et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res. 2011;108(3):314-323.
66. Frisdal E, et al. Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the pro-inflammatory response. J Biol Chem. 2011;286(35):30926-30936.